Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Receives Average Recommendation of “Hold” from Brokerages

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has been assigned a consensus rating of “Hold” from the five analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $41.00.

A number of analysts have issued reports on ETON shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Tuesday, April 21st. Wall Street Zen raised Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. HC Wainwright raised their target price on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Zacks Research downgraded Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 17th. Finally, B. Riley Financial raised their target price on Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, March 20th.

Institutional Trading of Eton Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Millennium Management LLC boosted its holdings in shares of Eton Pharmaceuticals by 156.3% in the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after acquiring an additional 217,042 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Eton Pharmaceuticals by 34.9% in the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock worth $2,274,000 after acquiring an additional 45,341 shares during the period. Jane Street Group LLC boosted its holdings in shares of Eton Pharmaceuticals by 49.1% in the first quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock worth $1,245,000 after acquiring an additional 31,596 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Eton Pharmaceuticals by 114.5% in the second quarter. JPMorgan Chase & Co. now owns 242,580 shares of the company’s stock worth $3,457,000 after acquiring an additional 129,467 shares during the period. Finally, Legal & General Group Plc bought a new position in shares of Eton Pharmaceuticals in the second quarter worth $41,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Stock Performance

Shares of ETON opened at $35.00 on Friday. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62. The stock has a 50 day moving average of $25.52 and a 200 day moving average of $19.65. Eton Pharmaceuticals has a 12 month low of $13.09 and a 12 month high of $35.66. The company has a market capitalization of $958.65 million, a price-to-earnings ratio of -499.93 and a beta of 0.82.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.The firm had revenue of $24.27 million during the quarter, compared to analysts’ expectations of $22.31 million. As a group, sell-side analysts forecast that Eton Pharmaceuticals will post 0.82 earnings per share for the current year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.